Replies to post #3104 on UniCycive Therapeutics Inc (UNCY)

[Whalatane]

Yes, this claim is accurate. Unicycive Therapeutics has explicitly stated that it estimates the U.S. market opportunity for OLC to be in excess of $500 million.
B2i Digital
B2i Digital
+1
Revenue and Market Potential
Targeted Revenue: The company projects that OLC could achieve $500 million+ in annual sales by 2029, assuming a 4% to 5% market share in the U.S..
Addressable Market: The total U.S. market for hyperphosphatemia treatments is estimated at over $1 billion annually, with a global opportunity exceeding $2.5 billion.
Commercial Strategy: Unicycive intends to commercialize OLC using its own internal, targeted sales force of approximately 40–80 representatives to reach the core market of high-prescribing nephrologists.
Unicycive
Unicycive
+5
Key Commercial Milestones (Projected)
FDA Decision: A Prescription Drug User Fee Act (PDUFA) target action date is set for June 29, 2026.
Product Launch: Pending approval, a commercial launch is anticipated in the third quarter of 2026.
Cash Runway: As of late March 2026, the company reported $54.9 million in cash and marketable securities, which it expects will fund operations into 2027.
Unicycive
Unicycive
+2

---------------------------------------------------------
So my attempt to explain this . Its the revenue per monthly script of OLC vs the revenue of monthly script pf say Sevelmar ( Renvela )
If the monthly revenue for OLC is $2,000 a month and the monthly revenue for generic Selevmar is $200 a month you only need a small percentage of the market for OLC to get to 50% of the Total revenue generated by pho binders in the US .

So 1,000 scripts of OLC X $2,000 per script per month = $2m
1,000 scripts of Selevmar at $200 per script per month = $200,000

So if the total market was $4m a month
1,000 script of OLC gets 50% of that ...ie 10% of market scripts generates about 50% of total market revenue
So you need
10,000 scripts of Selevmar to get the remaining 50% of that total monthly market

My quick take .
Might write a post later on why 10% of dialysis population would want XPHOZAH , another 20% or so would want an iron based pho drug and at least another 10% would want a third drug
Max market potential is probably around 50% of total dialysis population for OLC ...if cost , distribution etc weren't factors

Kiwi